TABLE 3.
Data extracted from studies included for the updated systematic review investigating the effects of randomized controlled dietary intervention(s) and/or cointervention on inflammatory markers in adults with nonalcoholic fatty liver disease for the intervention effects of cytokines
|
High-sensitivity C-reactive protein | |||||||
|---|---|---|---|---|---|---|---|
| Reference | Diet | Unit | Preintervention serum concentration | Postintervention serum concentration | P value | Computed change | Mean change conc. (95% CI), mg/mL |
| Dietary intervention alone | |||||||
| Baldry et al. (2017) [46] | Very-low energy diet; food-based diet | mg/L | 8.2 (42.8) | 5.1 (21.7) | 0.007 | −37.8% | |
| Very-low energy diet; meal-replacement plan | 9.6 (29.1) | 6.4 (21.8) | 0.004 | −33.3% | |||
| Kani et al. (2014) [45] | Low calorie | mg/L | nd | nd | nd | −1.0 ± 0.6b | |
| Low calorie, low carbohydrate | nd | nd | nd | −1.1 ± 0.6b | |||
| Low calorie, low carbohydrate, soy containing | nd | nd | 0.01 | −8.0 ± 1.0b | |||
| Marin-Alejandre et al. (2019) [42] | Hypocaloric diet (AHA) | mg/L | 6.5 + 1.9 | 3.2 + 0.4 | 0.250 | −51.0% | |
| Hypocaloric Mediterranean diet (FLIO) | 4.0 + 0.60 | 1.8 + 0.20 | 0.001 | −55.0% | |||
| Marina et al. (2014) [83] | Low-fat diet | mg/L | 3.3 ± 2.8 | 2.8 ± 2.5 | ns | −15.1% | |
| High-fat diet | 2.3 ± 1.9 | 2.2 ± 1.2 | ns | −4.3% | |||
| Razavi Zade et al. (2016) [55] | Hypocaloric diet | mg/L | 4.9 ± 3.4 | 4.6 ± 2.8 | 0.08 | −6.1% | |
| DASH diet | 4.8 ± 3.3 | 3.6 ± 2.7 | 0.004 | −25.0% | |||
| Ristic-Medic et al. (2020) [44] | Hypocaloric (NIHFN) | mg/L | 2.10 (0.98,3.20)a | 0.77 (0.54,1.27)a | 0.008 | −63.0% | |
| Hypocaloric Mediterranean diet (NIHFN) | 1.02 (0.75,2,23)a | 0.81 (0.34,1.40)a | 0.000 | −21.0% | |||
| Dietary intervention plus cointervention | |||||||
| Chan et al. (2010) [51] | Hypocaloric diet, Low fat | mg/L | 2.2 ± 1.3 | 2.4 ± 1.6 | nd | 9.1% | |
| Hypocaloric diet, Low fat + cholesterol-lowering agent | 3.9 ± 3.8 | 2.2 ± 2.7 | <0.05∗ | −43.6% | |||
| Kaliora et al. (2016) [81] | Isocaloric diet | mg/L | 2.4 ± 3.0 | 0.84 ± 1.1 | 0.023 | −65.0% | |
| Isocaloric diet + Corinthian currants | 2.1 ± 1.8 | 0.82 ± 0.7 | 0.002 | −60.9% | |||
| Malaguarnera et al. (2010) [69] | NCEP-ATPIII | mg/L | 8.7 ± 3.4 | 7.4 ± 3.2 | ≥ 0.05 | −14.9% | |
| NCEP-ATPIII + L-carnitine | 9.1 ± 3.2 | 5.2 ± 3.1 | <0.001∗ | −42.9% | |||
| Dietary intervention plus supplementation | |||||||
| Abedi et al. (2018) [48] | Energy-restricted diet plus Vitamin E supplement | mg/L | 4.1 + 4.6 | 3.4 + 4.1 | 0.008 | −17.0% | |
| Energy-restricted diet plus CLA and Vitamin E supplement | 3.6 + 4.6 | 2.6 + 3.8 | 0.001 | −28.0% | |||
| Abhari et al. (2020) [73] | Energy-balanced (NHLBI-EB) plus placebo | mg/L | 5797.3 ± 3497.5 | 6049.7 ± 4740.0 | 0.459 | 259.67 ± 1274.55b | |
| Energy-balanced (NHLBI-EB) plus synbiotic (B. coagulans) | 5183.9 ± 3497.1 | 4397.5 ± 3616.0 | 0.119 | −793.38 ± 2174.87b | |||
| Behrouz et al. (2020) [56] | Energy-balanced diet (NHLBI-EB) plus placebo | pg/ml | 9.2 + 4.5 | 6.9 + 3.7 | 0.03 | −25.0% | |
| Energy-balanced diet (NHLBI-EB) plus probiotic and prebiotic placebo | 9.3 + 4.3 | 6.3 + 4.9 | 0.001 | −32.0% | |||
| Energy-balanced diet (NHLBI-EB) plus prebiotic and probiotic placebo | 9.9 + 5.8 | 6.1 + 5.0 | 0.001 | −38.0% | |||
| Cerletti et al. (2020) [57] | Mediterranean diet | mg/L | 2.97 (0.36, 4.67)a | 2.52 (1.39, 4.30)a | 0.420 | −15.0% | |
| Mediterranean diet plus nutraceutical | 2.20 (1.40, 4.00)a | 17.1 (1.80, 3.20)a | 0.120 | −19.0% | |||
| Darand et al. (2019) [58] | Energy balanced diet (NHLBI-EB) plus placebo. | mg/L | 5057.53 + 3,291.26 | 4509.86 + 3,288.4 | 0.480 | −11.0% | |
| Energy balanced diet (NHLBI-EB) plus Nigella sativa seed powder supplement | 4959.63 + 3,391.89 | 3514.22 + 3982.89 | 0.000 | −29.0% | |||
| Eslami et al. (2019) [40] | Hypocaloric diet | mg/L | 3.51 + 1.3 | 3.14 + 1.4 | 0.18 | −11.0% | |
| Hypocaloric diet plus soy milk | 3.68 + 1.82 | 2.34 + 1.59 | <0.001∗ | −36.0% | |||
| Eslamparast et al. (2014) [68] | Energy-balanced diet (NHLBI-EB) | mg/L | nd | nd | −1.04 (−1.5 to −0.6) | ||
| Energy-balanced diet (NHLBI-EB) + synbiotic supplement | nd | nd | −2.30 (−3.0 to −1.5) | ||||
| Faghihzadeh et al. (2014) [60] | Energy-balanced diet (NHLBI-EB) | mg/L | 3.20 + 1.85 | 3.4 + 2.13 | 0.861 | 6.0% | |
| Energy balanced diet (NHLBI-EB) plus trans-resveratrol supplement | 3.02 + 1.04 | 2.11 + 0.96 | 0.011 | −30.0% | |||
| Haidari et al. (2020) [61] | Energy-restricted normal-protein diet | mg/L | 4.9 + 1.5 | 3.5 + 0.1 | <0.001∗∗ | −29.0% | |
| Energy-restricted normal-protein diet plus BCX | 5.0 + 1.9 | 3.2 + 0.1 | <0.001∗∗ | −36.0% | |||
| Energy-restricted High Protein Diet | 4.7 + 1.5 | 2.6 + 0.1 | <0.001∗∗ | −45.0% | |||
| Energy-restricted High Protein Diet plus BCX | 4.8 + 1.9 | 2.4 + 0.1 | <0.001∗∗ | −50.0% | |||
| Kavyani et al. (2021) [75] | Low calorie diet plus placebo | ng/mL -1 | 11.66 ± 2.90 | 10.23 ± 2.37 | nd | −12.0% | |
| Low calorie diet plus Camelina Sativa oil & prebiotic | 10.49 ± 1.58 | 8.81 ± 2.29 | <0.05 | −16.0% | |||
| Malaguarnera et al. (2012) [49] | Hypocaloric (NCEP-ATPIII) diet | mg/L | 6.7 + 3.1 | 6.0 + 3.0 | ≥ 0.05 | −10.0% | |
| Hypocaloric diet (NCEP-ATPIII) plus probiotic and prebiotic supplement | 7.0 + 3.4 | 4.1 + 3.1 | <0.001∗ | −41.0% | |||
| Mofidi et al. (2017) [70] | NHLBI-EB Diet | mg/L | nd | nd | −0.42 ± 0.1b | ||
| NHLBI-EB Diet plus synbiotic supplement | nd | nd | −1.16 ± 0.4b | ||||
| Moradi et al. (2021) [76] | Energy-restricted diet (AHA) plus placebo | mg/L | 5.20 ± 2.73 | 4.75 ± 1.04 | 0.425 | −9.0% | |
| Energy-restricted diet (AHA) plus Chromium Picolinate supplement | 4.32 ± 1.42 | 3.61 ± 1.36 | 0.004 | −16.0% | |||
| Nomi-Golzar et al. (2021) [52] | Low-calorie diet | ng/mL | 5.0 ± nd | 5.1 ± nd | >0.05 | 2.0% | |
| Low-calorie diet plus Hydroxy-citric acid supplement | 4.9 ± nd | 5.1 ± nd | >0.05 | 4.0% | |||
| Pour et al. (2020) [77] | Healthy diet plus placebo | ng/mL | 5.48 ± 5.17 | 4.37 ± 3.90 | 0.248 | −20.0% | |
| Healthy diet plus saffron supplement | 5.30 ± 4.48 | 2.49 ± 2.25 | <0.01 | −53.0% | |||
| Rahimlou et al. (2016) [71] | NHLBI-EB Diet | mg/L | 4.8 ± 0.2 | 2.8 ± 0.2 | 0.005 | −41.7% | |
| NHLBI-EB Diet plus ginger supplement | 4.6 ± 0.1 | 3.4 ± 0.1 | 0.007 | −26.1% | |||
| Rafie et al. (2020) [62] | NHLBI-EB Diet | mg/L | 2.26 (1.16,3.98)a | 2.12 (0.98,3.78)a | 0.128 | −-6.0% | |
| NHLBI-EB Diet plus ginger supplement | 2.40 (1.14,3.58)a | 1.82 (0.88,3.18)a | 0.001 | −24.0% | |||
| Shahmoham-madi et al. (2017) [72] | NHLBI-EB Diet | mg/L | 1.5 (0.4, 2.7)a | 1.5 (0.4, 3.0)a | 0.846 | 0.0% | |
| NHLBI-EB Diet plus GCBE supplement | 1.4 (0.4, 3.4)a | 1.1 (0.5, 2.3)a | <0.001∗ | −21.4% | |||
| Yari et al. (2016) [82] | NHLBI-EB Diet | mg/L | nd | nd | −1.02 (−1.6 to −0.5) | ||
| NHLBI-EB Diet plus flaxseed supplement | nd | nd | −2.05 (−2.6 to 1.5) | ||||
| Yari et al. (2021) [79] | Hypocaloric diet | mg/L | 3.81 + 3.30 | 3.04 + 2.67 | 0.388 | −20.0% | |
| Hypocaloric diet plus hesperidin | 4.17+ 2.62 | 2.98 + 2.34 | 0.005 | −28.0% | |||
| Hypocaloric diet plus flaxseed | 4.68 + 2.04 | 4.80 + 6.72 | 0.992 | 2.0% | |||
| Hypocaloric diet plus hesperidin and flaxseed | 6.19 + 5.50 | 4.62 + 4.93 | <0.001∗ | −25.0% | |||
| Interleukin-6 | |||||||
|---|---|---|---|---|---|---|---|
| Reference | Diet | Unit | Pre- | Post- | P value | Computed change | Mean change (95%CI), mg/mL |
| Dietary intervention alone | |||||||
| Baldry et al. (2017) [46] | Very-low energy diet; food-based diet | pg/mL | 3.7 (10.4)c | 3.7 (25.4)c | 0.175 | 0.0% | |
| Very-low energy diet; meal-replacement plan | 4.5 (42.6)c | 3.7 (25.4)c | 0.04 | −17.8% | |||
| Marina et al. (2014) [83] | Low-fat diet | pg/mL | 1.08 (1.09)c | 1.01 (1.14)c | ≥ 0.05 | −6.5% | |
| High-fat diet | 0.91 (1.4)c | 0.83 (2.4)c | ≥ 0.05 | −8.8% | |||
| Markova et al. (2016) [80] | Plant-protein isocaloric diet | pg/mL | 1.4 ± 1.4 | 1.4 ± 1.5 | 0.816 | −1.4% | |
| Animal protein isocaloric | 1.1 ± 1.1 | 0.9 ± 0.7 | 0.166 | 21.7% | |||
| Dietary intervention plus cointervention | |||||||
| Chan et al. (2010) [51] | Hypocaloric diet, Low fat | pg/mL | 0.8 ± 0.2 | 0.9 ± 0.4 | ≥0.05 | 12.5% | |
| Hypocaloric diet, low fat + cholesterol-lowering agent | 1.1 ± 0.4 | 0.9 ± 0.5 | <0.05∗ | −18.2% | |||
| Kaliora et al. (2016) [81] | Isocaloric diet | pg/mL | 1.7 ± 3.2 | 1.3 ± 1.4 | 0.322 | −23.5% | |
| Isocaloric diet + Corinthian currants | 1.6 ± 1.4 | 0.9 ± 0.5 | 0.009 | −43.7% | |||
| Dietary intervention plus supplementation | |||||||
| Abedi et al. (2018) [48] | Energy-restricted diet plus Vitamin E | pg/mL | 23.11 + 16.80 | 22.10 + 15.78 | 0.610 | −4.0% | |
| Energy-restricted diet plus CLA and Vitamin E | 16.18 + 5.95 | 15.27 + 5.5 | 0.042 | −6.0% | |||
| Amanat et al. (2017) [66] | Weight-management diet | pg/mL | 18.2 ± 3.4 | 18.1 ± 1.8 | 0.8 | 0.5% | |
| Weight management + soy isoflavone | 18.8 ± 3.1 | 16.6 ± 2.5 | 0.01 | −11.7% | |||
| Duseja et al. (2019) [59] | Hypocaloric diet | pg/mL | 112.8 + 83.7 | 141.4 + 107.3 | 0.507 | 25.0% | |
| Hypocaloric diet plus multistrain probiotic | 125.6 + 95.3 | 100.6 + 74.7 | 0.041 | −20.0% | |||
| Faghihzadeh et al. (2014) [60] | NHLB-EBI Diet | pg/dL | 7.22 + 4.73 | 6.65 + 4.23 | 0.677 | −8.0% | |
| NHLBI-EB Diet plus trans-resveratrol supplement | 5.49 + 2.64 | 3.96 + 1.91 | 0.034 | −28.0% | |||
| Ferro et al. (2020) [74] | Mediterranean diet plus placebo | pg/mL | 1.68 ± 0.8 | 2.57 ± 1.3 | <0.001 | 53.0% | |
| Mediterranean diet plus BPF and CYC | 1.92 ± 0.9 | 3.03 ± 1.3 | <0.001 | 58.0% | |||
| Haidari et al. (2020) [61] | Energy-restricted normal-protein diet | pg/mL | 6.1 + 2.2 | 4.8 + 0.3 | <0.001∗∗ | −21.0% | |
| Energy-restricted normal-protein diet plus BCX | 5.9 + 2.2 | 4.0 + 0.3 | −32.0% | ||||
| Energy-restricted High Protein Diet | 6.6 + 2.2 | 3.5 + 0.3 | −47.0% | ||||
| Energy-restricted High Protein Diet plus BCX | 6.4 + 1.9 | 3.1 + 0.3 | −51.0% | ||||
| Moradi et al. (2021) [76] | Energy-restricted diet plus placebo | pg/mL | 39.23 ± 16.29 | 39.57 ± 15.25 | 0.902 | 1.0% | |
| Energy-restricted diet plus Chromium Picolinate supplement | 36.69 ± 17.70 | 28.76 ± 14.20 | 0.002 | −22.0% | |||
| Rezaei et al. (2019) [64] | Hypocaloric diet plus sunflower oil | pg/mL | 8.5 + 4.5 | 8.3 + 3.3 | 0.400 | −2.0% | |
| Hypocaloric diet plus olive oil | 7.5 + 1.6 | 7.7 + 1.8 | 0.400 | −3.0% | |||
| Rezaei et al. (2020) [65] | Hypocaloric diet plus sunflower oil | pg/mL | 8.4 + 4.5 | 8.29 + 3.27 | 0.430 | −1.0% | |
| Hypocaloric diet plus flaxseed oil | 7.63 + 1.29 | 7.35 + 0.89 | 0.100 | −4.0% | |||
| Tumor necrosis factor-alpha | |||||||
|---|---|---|---|---|---|---|---|
| Reference | Diet | Unit | Pre- | Post- | P value | Computed change | Mean change (95% CI), mg/mL |
| Dietary intervention alone | |||||||
| Markova et al. (2016) [80] | Plant-protein isocaloric diet | ng/mL | 4.5 ± 2.6 | 3.8 ± 2.4 | 0.016 | −15.6% | |
| Animal protein isocaloric diet | 4.3 ± 2.8 | 4.4 ± 2.2 | 0.925 | 2.3% | |||
| Dietary intervention plus cointervention | |||||||
| Chan et al. (2010) [51] | Hypocaloric, low-fat diet | ng/mL | 5.4 ± 1.6 | 5.4 ± 1.9 | ≥ 0.05 | 0.0% | |
| Hypocaloric, low-fat diet + cholesterol-lowering agent | 6.3 ± 1.9 | 5.4 ± 2.3 | <0.05∗ | −14.3% | |||
| Kaliora et al. (2016) [81] | Isocaloric diet | ng/mL | 1.3 ± 1.0 | 0.8 ± 0.5 | 0.004 | −38.5% | |
| Isocaloric diet + Corinthian currants | 0.9 ± 1.0 | 1.3 ± 0.5 | 0.063 | 44.4% | |||
| Malguarnera et al. (2010) [69] | NCEP-ATPIII diet | ng/mL | 1.38 ± 0.22 | 1.30 ± 0.21 | ≥ 0.05 | −5.8% | |
| NCEP-ATPIII diet + L-carnitine | 1.44 ± 0.28 | 1.08 ± 0.15 | <0.001∗ | −25.0% | |||
| Dietary intervention plus supplementation | |||||||
| Abedi et al. (2018) [48] | Energy-restricted diet plus Vitamin E supplement | pg/mL | 26.59 + 23.28 | 25.57 + 22.83 | 0.020 | −3.0% | |
| Energy-restricted diet plus CLA and Vitamin E supplement | 64.25 + 94.18 | 37.53 + 51.13 | 0.010 | −41.0% | |||
| Abhari et al. (2020) [73] | NHLB-EB Diet plus placebo | pg/mL | 18.4 ± 1.79 | 16.95 ± 2.37 | 0.054 | −1.68 ± 2.82b | |
| NHLB-EB Diet plus synbiotic (B. coagulans) | 17.35 ± 4.89 | 14.0 ± 1.29 | 0.010 | −3.35 ± 5.24b | |||
| Amanat et al. (2017) [66] | Weight-management diet | ng/mL | 1.8 ± 2.6 | 1.8 ± 2.6 | 0.990 | 0.0% | |
| Weight-management diet + soy isoflavone | 1.8 ± 2.5 | 1.6 ± 2.4 | 0.010 | −11.1% | |||
| Darand et al. (2019) [58] | NHLBI-EB Diet | pg/mL | 18.68 + 2.18 | 17.44 + 1.77 | 0.010 | −6.0% | |
| NHLBI-EB Diet plus Nigella sativa seed powder | 17.71 + 6.47 | 14.02 + 1.91 | 0.010 | −21.0% | |||
| Duseja et al. (2019) [59] | Hypocaloric diet | pg/mL | 190.00 + 131.10 | 243.15 + 167.10 | 0.917 | 28.0% | |
| Hypocaloric diet plus multistrain probiotic preparation | 207.9 + 102.2 | 107.8 + 94.4 | 0.911 | −48.0% | |||
| Eslamparast et al. (2014) [68] | NHLBI-EB Diet | ng/mL | nd | nd | −0.59 (−0.8 to −0.3) | ||
| NHLBI-EB Diet plus synbiotic supplement | nd | nd | −1.4 (−1.7 to −1.1) | ||||
| Faghihzadeh et al. (2014) [60] | NHLBI-EB Diet plus placebo | pg/mL | 16.55 + 4.79 | 20.62 + 10.88 | 0.094 | 25.0% | |
| NHLBI-EB Diet plus trans-resveratrol supplement | 19.96 + 18.80 | 16.25 + 5.47 | 0.317 | −19.0% | |||
| Ferro et al. (2020) [74] | Mediterranean diet plus placebo | pg/mL | 3.08 ± 0.6 | 1.53 ± 0.8 | <0.001 | −50.0% | |
| Mediterranean diet plus BPF and CYC | 3.56 ± 3.9 | 2.04 ± 2.4 | 0.002 | −43.0% | |||
| Malaguarnera et al. (2012) [49] | Hypocaloric (NCEP-ATPIII) diet plus placebo | ng/mL | 1.24 + 0.26 | 1.12 + 0.31 | ≥ 0.05 | −10.0% | |
| Hypocaloric diet (NCEP-ATPIII) plus probiotic and prebiotic supplement | 1.28 + 0.28 | 0.83 + 0.36 | <0.001∗ | −35.0% | |||
| Mofidi et al. (2017) [70] | NHLBI-EB Diet | ng/mL | −0.3 ± 0.2c | ||||
| NHLBI-EB Diet plus flaxseed supplement | −1.22 ± 0.8c | ||||||
| Moradi et al. (2021) [76] | Energy-restricted diet plus placebo | pg/mL | 72.6 ± 34.2 | 77.2 ± 37.4 | 0.367 | 6.0% | |
| Energy-restricted diet plus Chromium Picolinate supplement | 89.8 ± 40.8 | 70.2 ± 39.4 | 0.501 | −22.0% | |||
| Pour et al. (2020) [77] | Healthy diet plus placebo | pg/mL | 194.44 ± 99.45 | 181.60 ± 96.29 | 0.026 | −7.0% | |
| Healthy diet plus saffron supplement | 207.31 ± 102.61 | 193.15 ± 95.10 | 0.019 | −7.0% | |||
| Rafie et al. (2020) [62] | NHLBI-EB Diet plus placebo | pg/mL | 11.63 + 1.77 | 11.57 + 1.23 | 0.880 | 0.0% | |
| NHLBI-EB Diet plus ginger supplement | 11.71 + 1.02 | 11.40 + 1.40 | 0.308 | −3.0% | |||
| Rahimlou et al. (2016) [71] | NHLBI-EB Diet | ng/mL | 3.0 ± 0.2 | 2.8 ± 0.2 | 0.003 | −6.7% | |
| NHLBI-EB Diet plus ginger supplement | 4.7 ± 0.4 | 3.5 ± 0.4 | 0.00 | −25.5% | |||
| Shahmoham-madi et al. (2017) [72] | NHLBI-EB Diet | ng/mL | 8.2 ± 3.2 | 8.8 ± 4.1 | 0.279 | 7.3% | |
| NHLBI-EB Diet plus GCBE supplement | 9.6 ± 3.9 | 8.6 ± 5.0 | 0.161 | −10.4% | |||
| Spadaro et al. (2008) [47] | AHA diet | ng/mL | 3.1 ± 0.4 | 3.0 ± 0.7 | ≥ 0.05 | −3.2% | |
| AHA diet + n-3 PUFA supplement | 3.3 ± 0.5 | 2.7 ± 0.5 | <0.05 | −18.2% | |||
| Yari et al. (2016) [82] | NHLBI-EB Diet | ng/mL | −0.14 (−0.07 to −0.2) | ||||
| NHLBI-EB Diet plus flaxseed supplement | −1.30 (−0.4 to 2.2) | ||||||
| Yari et al. (2021) [79] | Hypocaloric diet (NHLBI-EB) | pg/mL | 22.36 + 5.61 | 20.16 + 5.93 | 0.037 | −10.0% | |
| Hypocaloric diet plus hesperidin | 27.87 + 12.69 | 21.31 + 6.95 | 0.001 | −23.0% | |||
| Hypocaloric diet plus flaxseed | 19.46 + 5.41 | 18.97 + 5.64 | 0.383 | −2.0% | |||
| Hypocaloric diet plus hesperidin and flaxseed | 26.18 + 6.39 | 19.87 + 4.66 | <0.001∗ | −24.0% | |||
1Values are mean ± SD or % change (calculated from means) unless otherwise indicated.
2 a Mean (minimum, maximum);
bMean change + SEM.
3∗Statistically significant. P<0.05 significant; ∗∗ Multivariable adjusted.
4AHA, American Heart Association; BCX, β-Cryptoxanthin; CLA, conjugated linoleic acid; FLIO, Fatty Liver in Obesity; NCEP-ATPIII, National Cholesterol Education Program Adult Treatment Panel III; NHLBI-EB, National Heart Lung and Blood Institute-Energy Balanced; NIHFN, National Institute of Health & Food & Nutrition; ns, nonsignificant.